In 2006. Maha Hussain and colleagues made a very important observation from SWOG 9346 that PSA nadir after ADT in mHSPC predicted overall survival. PSA nadir remains strongly prognostic, even in an era of novel ART therapies! Sema4 Icahn School of Medicine at Mount Sinai pubmed.ncbi.nlm.nih.gov/16921051/

Nick Vogelzang was Chair of the GU Committee when I went to my first CALGB meeting in 1996. He gave me the opportunity to introduce a concept for a phase 2 trial and supported me every step of the way. He was a true giant with an enormous heart—for his patients and colleagues.

Really interesting conversation about how to get to a data environment that accelerates improvements in human health. Icahn School of Medicine at Mount Sinai Sema4 GeneDx

Our paper on somatic NGS testing suggests increasing value to molecular testing in prostate cancer in a changing treatment landscape. Does it matter if all patients receive PARPi? I would argue yes. Sema4 Icahn School of Medicine at Mount Sinai frontiersin.org/articles/10.33…

Cheaper sequencing will allow for more “statistical oomph to discover stuff” according to Bruce Gelb. ⁦Mount Sinai Health System⁩. Data science and clinical trials will need to catch up to help patients benefit from all of the genetic data. ⁦Sema4⁩ nytimes.com/2022/10/12/bus…

From 2013 courtesy of Mary Ellen!

I am incredibly excited to join you Chuck, Howard Soule and the whole Prostate Cancer Foundation team on this critical mission!

Just in #ASCODailyNews ASCO: Interview with Charles Ryan CEO Prostate Cancer Foundation on the mission and vision of #ProstateCancerFoundation Congrats for building the next-gen investigators Howard Soule Andrea Miyahira Take a listen👉bit.ly/3gh9Wqa UroToday.com OncoAlert PCF Science

A wonderful opportunity to have a leadership role at Mount Sinai Health System and Icahn School of Medicine at Mount Sinai as Director of Prostate Medical Oncology. Many outstanding GU colleagues and amazing clinical/scientific opportunities! #collaboration linkedin.com/jobs/view/3371…

It was great to learn about all the progress that Dr Petereit and the team at Walking Forward have been making at addressing cancer disparities in #AmericanIndian health care. Avera Health Monument Health @NCICRCHD Dr. Kimryn Rathmell

Platinum agents are active in mCRPC, but who responds? DDR mutations are relevant but are there other blood-based biomarkers? Funded by Prostate Cancer Foundation, this paper was a long time coming but is relevant in era of #NEPC and lethal #prostatecancer. Mount Sinai Health System academic.oup.com/oncolo/advance…

Is there a benefit to #LHRHantagonists (vs #agonists) in risk of #CV events in prostate cancer pts? This review suggests sparse evidence for a difference. Prob most important is make sure to have good CV evaluation prior to initiating any ADT. pubmed.ncbi.nlm.nih.gov/35862876/

We Prostate Cancer Foundation are proud to take this on, filling a much needed gap regarding screening + detection, treatment of localized disease, and treatment of advanced disease. Topics related to black men have been ignored in prior guidelines. William Oh MD will convene the panel. More soon!

William K. Oh, MD, and Charles J. Ryan, MD on Prostate Cancer Disparities and the ‘Last Mile’ Problem ascopost.com/issues/june-25… #pcsm #prostatecancer #healthequity Icahn School of Medicine at Mount Sinai Charles Ryan Prostate Cancer Foundation

Thought Leaders of the Future Meeting #prostatecancer underway with some incredible leaders in GU Cancer Research 🤩Pathways to leadership and “keys to success” #prostatecancer Prostate Cancer Foundation UroToday.com

Prostate Cancer Foundation Thought Leaders of the Future Program, August 10-12, Los Angeles👉Congrats and thanks to Charles Ryan William Oh MD Howard Soule Andrea Miyahira and the PCF team for organizing this fantastic training/ mentoring event focusing on young investigators pursuing